Market Intelligence Center  12 hrs ago  Comment 
After Friday’s trading in Sanofi-Aventis (SNY) the algorithms behind MarketIntelligenceCenter.com's Artifical Intelligence Center picked out a trade that offers a 3.58% or 22.15% (for comparison purposes only), while providing 4.21% downside...
FiercePharma  Jan 15  Comment 
Sanofi and Regeneron are hard at work on a number of promising monoclonal antibodies, but Sanofi needs more manufacturing capacity to produce them. Instead of building its own like some of its peers, the French company has struck a deal to tap...
MedPage Today  Jan 13  Comment 
(MedPage Today) -- Addition of oxaliplatin to FOLFIRI and bevacizumab doubled 5-year survival.
FiercePharma  Jan 13  Comment 
When the JP Morgan Healthcare Conference rolls around, it's always a case of so much news, so little time (and space). So, we're collecting some of the bigger stories here.
Benzinga  Jan 12  Comment 
Speaking to Benzinga, Griffin Securities Analyst Dr. Keith Markey said that after MannKind Corporation (NASDAQ: MNKD) founder Alfred Mann retires from his role as CEO, the new management will probably not pursue a merger with Sanofi SA (ADR)...
TheStreet.com  Jan 12  Comment 
Updated with additional information from 1:35 pm EST SAN FRANCISCO ( TheStreet) -- MannKind CEO Al Mann is retiring and the company's inhaled insulin device Afrezza still has no publicly disclosed commercial launch date.  Elias...
Motley Fool  Jan 8  Comment 
Sanofi has made a $50 million milestone payment to MannKind, but Afrezza's success or failure is far more important to MannKind this year.
FiercePharma  Jan 8  Comment 
U.K. officials have decided which drugs to toss off the Cancer Drug Fund, which pays for drugs rejected by cost-effectiveness gatekeepers. Reportedly, Novartis, Sanofi and Eisai treatments are among them.


Very nice site!

Wikinvest © 2006, 2007, 2008, 2009, 2010, 2011, 2012. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.
Powered by MediaWiki